Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP.

Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250.

2.

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.

Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM.

Cancer Res. 2004 Sep 1;64(17):6200-6.

3.
4.

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.

Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW.

Nucl Med Biol. 2000 May;27(4):339-46.

PMID:
10938467
5.

Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.

Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM.

J Nucl Med. 2016 Mar;57(3):444-52. doi: 10.2967/jnumed.115.162339. Epub 2015 Oct 1.

6.

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE.

Bioconjug Chem. 2000 May-Jun;11(3):327-34.

PMID:
10821648
7.

PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.

Cai W, Olafsen T, Zhang X, Cao Q, Gambhir SS, Williams LE, Wu AM, Chen X.

J Nucl Med. 2007 Feb;48(2):304-10.

8.

Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.

Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, Stabin MG, Brechbiel MW.

Radiat Res. 2002 Jun;157(6):633-41.

PMID:
12005541
9.

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.

J Nucl Med. 1997 Dec;38(12):1944-50.

10.

124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM.

J Nucl Med. 2003 Dec;44(12):1962-9.

11.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25.

PMID:
16173788
12.

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK.

Clin Cancer Res. 2011 Mar 15;17(6):1509-20. doi: 10.1158/1078-0432.CCR-10-1654. Epub 2010 Dec 21.

13.

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD.

Br J Cancer. 1998 May;77(9):1405-12.

14.

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL, et al.

Cancer Res. 1994 Aug 15;54(16):4362-70.

15.

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM.

Clin Cancer Res. 2006 Mar 1;12(5):1599-605.

16.

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM.

Cancer Res. 1998 Feb 1;58(3):485-90.

17.

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.

J Nucl Med. 2005 Dec;46(12):2061-7.

19.

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM.

Mol Immunol. 1999 May;36(7):433-45.

PMID:
10449096
20.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

Supplemental Content

Support Center